Rallybio and Avenzo postpone merger closing past November 6, 2026 target

Rallybio Corporation disclosed on November 6, 2026 that its planned merger with Avenzo Therapeutics, Inc. will not close as previously targeted. The company had previously disclosed that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipated the merger transactions under the Agreement and Plan of Merger and Reorganization dated May 31, 2026, among Rallybio, Avenzo Therapeutics, Inc. and Farmington Merger Sub, Inc., would close on November 6, 2026.¹

That timeline has now slipped. Certain conditions tied to the listing of the company's shares following the closing have not been satisfied, so the parties have decided to postpone the closing while they continue pursuing the needed listing approvals.¹

The delay also affects a previously announced cash distribution to shareholders. Because the closing was postponed, Rallybio did not deposit the funds for that distribution with Computershare on November 5, 2026.¹ As a result, the previously announced payment date and ex-dividend date for the cash distribution may be delayed.¹

Rallybio did not specify a new target closing date in the filing. The company said it will provide further updates it deems appropriate or necessary in accordance with applicable law and regulations.¹ The filing was signed by Chief Financial Officer Jonathan I. Lieber.